Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions
Executive Summary
Long-planned OND 'modernization' to better match workflow, allow more time with stakeholders includes proposed restructuring that would boost number of offices overseeing review operations (adding four for a total of nine) and drug review divisions (adding 11 for a total of 30).
You may also be interested in...
Khushboo Sharma: Improving Regulatory Science, From Industry To FDA And Back
From pre-med to pharma lab rat to deputy director of operations at the FDA, Khushboo Sharma, a 2021 In Vivo Rising Leader and current VP of science and regulatory affairs at BIO, has spent her career pursuing a goal she says the FDA and biopharma industry have in common: ensuring that innovative drugs get to patients.
Meeting Expectations: US FDA Communications Getting High Marks – Before COVID, At Least
FDA’s interactions with sponsors to support drug development activities are generally timely and effective – but industry still sees room for improvement in assuring ‘best practices’ are followed across all divisions.
US FDA's Office Of New Drugs Reorganization Approved, But Not Happening Overnight
OND will grow to eight offices and 27 clinical divisions, which is slightly different than an early proposal.